

EAU Guidelines on Primary Urethral Carcinoma

G. Gakis, J.A. Witjes, M. Bruins, E. Comp erat, N.C. Cowan,
V. Hern andez, T. Lebret, A. Lorch, M.J. Ribal,
A.G. van der Heijden, E. Veskim ae
Guidelines Associates: M.E. Linares Espin os,
M. Rouanne, Y. Neuzillet

TABLE OF CONTENTS

PAGE

| | | |
|----|--|----|
| 1. | INTRODUCTION | 4 |
| | 1.1 Aims and scope | 4 |
| | 1.2 Panel composition | 4 |
| | 1.3 Publication history and summary of changes | 4 |
| | 1.3.1 Summary of changes | 4 |
| 2. | METHODS | 5 |
| | 2.1 Data identification | 5 |
| | 2.2 Review | 5 |
| | 2.3 Future goals | 5 |
| 3. | EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY | 6 |
| | 3.1 Epidemiology | 6 |
| | 3.2 Aetiology | 6 |
| | 3.3 Histopathology | 6 |
| 4. | STAGING AND CLASSIFICATION SYSTEMS | 6 |
| | 4.1 Tumour, Node, Metastasis (UICC/TNM) staging system | 6 |
| | 4.2 Tumour grade | 7 |
| | 4.3 Guideline for staging and classification systems | 7 |
| 5. | DIAGNOSTIC EVALUATION AND STAGING | 7 |
| | 5.1 History | 7 |
| | 5.2 Clinical examination | 8 |
| | 5.3 Urinary cytology | 8 |
| | 5.4 Diagnostic urethrocytostcopy and biopsy | 8 |
| | 5.5 Radiological imaging | 8 |
| | 5.6 Regional lymph nodes | 8 |
| | 5.7 Summary of evidence and guidelines for diagnostic evaluation and staging | 8 |
| 6. | PROGNOSIS | 9 |
| | 6.1 Long-term survival after primary urethral carcinoma | 9 |
| | 6.2 Predictors of survival in primary urethral carcinoma | 9 |
| | 6.3 Summary of evidence for prognosis | 9 |
| 7. | DISEASE MANAGEMENT | 9 |
| | 7.1 Treatment of localised primary urethral carcinoma in males | 9 |
| | 7.1.1 Summary of evidence and guidelines for the treatment of primary urethral carcinoma in males | 10 |
| | 7.2 Treatment of localised urethral carcinoma in females | 10 |
| | 7.2.1 Urethrectomy and urethra-sparing surgery | 10 |
| | 7.2.2 Radiotherapy | 10 |
| | 7.2.3 Summary of evidence and guidelines for the treatment of localised urethral carcinoma in females | 10 |
| | 7.3 Multimodal treatment in advanced urethral carcinoma in both genders | 11 |
| | 7.3.1 Introduction | 11 |
| | 7.3.2 Preoperative platinum-based chemotherapy | 11 |
| | 7.3.3 Preoperative chemoradiotherapy in locally advanced squamous cell carcinoma of the urethra | 11 |
| | 7.3.4 Salvage treatment in recurrent primary urethral carcinoma after surgery for primary treatment | 11 |
| | 7.3.5 Summary of evidence and guidelines for multimodal treatment in advanced urethral carcinoma in both genders | 11 |
| | 7.4 Treatment of urothelial carcinoma of the prostate | 12 |
| | 7.4.1 Summary of evidence and guidelines for the treatment of urothelial carcinoma of the prostate | 12 |
| 8. | FOLLOW-UP | 12 |

| | | |
|-----|----------------------|----|
| 9. | REFERENCES | 12 |
| 10. | CONFLICT OF INTEREST | 16 |
| 11. | CITATION INFORMATION | 16 |

1. INTRODUCTION

1.1 Aims and scope

The aim of these guidelines is to deliver current evidence-based information on the diagnosis and treatment of patients with primary urethral carcinoma (UC). When the first carcinoma in the urinary tract is detected in the urethra, this is defined as primary UC, in contrast to secondary UC, which presents as recurrent carcinoma in the urethra after prior diagnosis and treatment of carcinoma elsewhere in the urinary tract. Most often, secondary UC is reported after radical cystectomy for bladder cancer [1, 2] (see Chapter 7.4 of the EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer [MIBC] [2]).

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account.

Guidelines are not mandates and do not purport to be a legal standard of care.

1.2 Panel composition

The EAU Guidelines Panel on MIBC is responsible for this publication. This is an international multidisciplinary group of clinicians, including urologists, a pathologist, an oncologist and a radiologist. Members of this panel have been selected based on their expertise to represent the professionals treating patients suspected of suffering from urethral carcinoma. All experts involved in the production of this document have submitted potential conflict of interest statements, which can be viewed on the EAU Website Uroweb: www.uroweb.org/guidelines/primary-urethral-carcinoma/.

1.3 Publication history and summary of changes

The Primary Urethral Carcinoma Guidelines were first published in 2013 [3]. This is the fourth update of this document.

1.3.1 Summary of changes

The literature for the complete document has been assessed and updated, where relevant.

A text section has been added:

- Section 7.3.3 - Salvage treatment in recurrent primary urethral carcinoma after surgery for primary treatment

New recommendations have been added to:

- Section 7.1.1 - Summary of evidence and guidelines for the treatment of primary urethral carcinoma in males

| Recommendation | LE | Strength rating |
|---|----|-----------------|
| Ensure complete circumferential assessment of the proximal urethral margin if penis-preserving surgery is intended. | 3 | Strong |

- Section 7.3.5 - Summary of evidence and guidelines for multimodal treatment in advanced urethral carcinoma in both genders

| Recommendations | LE | Strength rating |
|---|----|-----------------|
| Systemic therapy in advanced disease should be selected based upon histology of the tumour. | 3 | Strong |
| Offer salvage surgery or radiotherapy to patients with urethral recurrence after primary treatment. | 3 | Weak |

2. METHODS

2.1 Data identification

For the 2018 Primary Urethral Carcinoma Guidelines, new and relevant evidence has been identified, collated and appraised through a structured assessment of the literature. An updated systematic literature search was performed to identify studies reporting data on urethral malignancies since the prior search, covering a time frame between September 15th 2016 and November 8th 2017. Databases searched included Ovid (Medline), EMBASE and the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews. A total of 241 records were identified, retrieved and screened for relevance. A total of seven new references were included in this 2018 publication. A detailed search strategy is available online: <https://uroweb.org/guideline/primary-urethral-carcinoma/?type=appendices-publications>.

For the 2018 edition of the EAU Guidelines the Guidelines Office have transitioned to a modified GRADE methodology across all 20 guidelines [4, 5]. For each recommendation within the guidelines there is an accompanying online strength rating form which addresses a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation, references used in this text are graded according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [6];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words 'strong' or 'weak' [4, 5]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences. The strength rating forms will be available online.

Additional information can be found in the general Methodology section of this print, and online at the EAU website; <http://www.uroweb.org/guideline/>.

A list of Associations endorsing the EAU Guidelines can also be viewed online at the above address.

2.2 Review

This document was peer-reviewed prior to publication in 2015.

2.3 Future goals

The MIBC Guidelines Panel aims to systematically address the following key clinical topics for future updates of the Primary Urethral Carcinoma Guidelines:

- assessment of the accuracy of radiological imaging (MRI) for local staging of primary UC and its predictive value on clinical decision-making;
- the (long-term) efficacy of urethral-sparing surgery and radiochemotherapy for genital preservation in localised tumours;
- the prognostic impact of neoadjuvant and adjuvant treatment modalities in locally advanced disease;
- the prognostic impact of the extent of transurethral resection of the prostate prior to BCG treatment in urothelial malignancies of the prostatic urethra and ducts.

3. EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY

3.1 Epidemiology

Primary UC is considered a rare cancer, accounting for < 1% of all malignancies [7] (ICD-O3 topography code: C68.0) [8]. In early 2008, the prevalence of UC in the 28 European Union countries was 4,292 cases with an estimated annual incidence of 655 new cases [9]. The age-standardised ratio was 1.1 per million inhabitants (1.6/million in men and 0.6/million in women; with a male to female ratio of 2.9) [9]. There were differences between European regions; potentially caused by registration or classification [9]. Likewise, in an analysis of the Surveillance, Epidemiology and End Results (SEER) database, the incidence of primary UC peaked in the > 75 years age group (7.6/million). The age-standardised rate was 4.3/million in men and 1.5/million in women, and was almost negligible in those aged < 55 years (0.2/million) [10].

3.2 Aetiology

For male primary UC, various predisposing factors have been reported, including urethral strictures [11, 12], chronic irritation after intermittent catheterisation/urethroplasty [13-15], external beam irradiation therapy (EBRT) [16], radioactive seed implantation [17], and chronic urethral inflammation/urethritis following sexually transmitted diseases (i.e. condylomata associated with human papilloma virus 16) [18, 19]. In female UC, urethral diverticula [20-22] and recurrent urinary tract infections [23] have been associated with primary UC. Clear cell adenocarcinoma (AC) may also have a congenital origin [24, 25].

3.3 Histopathology

Both the Surveillance of Rare Cancers in Europe (RARECARE) project and SEER database have reported that urothelial carcinoma of the urethra is the predominant histological type of primary urethral cancer (54-65%), followed by squamous cell carcinoma (SCC) (16-22%) and AC (10-16%) [9, 10]. A recent SEER analysis of 2,065 men with primary UC (mean age: 73 years) found that UC was most common (78%), and SCC (12%) and AC (5%) were significantly less frequent [26]. In women, a recent report of the Dutch National Cancer Registry on primary urethral cancer reported that UC occurred in 45% of cases, followed by AC in 29%, SCC in 19%, and other histological entities in 6% [27].

4. STAGING AND CLASSIFICATION SYSTEMS

4.1 Tumour, Node, Metastasis (UICC/TNM) staging system

In men and women, UC is classified according to the 8th edition of the TNM classification [8] (Table 4.1). It should be noted that there is a separate TNM staging system for prostatic UC [8]. Of note, for cancers occurring in the urethral diverticulum, stage T2 is not applicable as urethral diverticula are lacking periurethral muscle [28].

Table 4.1: TNM classification (8th edition) for urethral carcinoma (UC) [8]

| T - Primary Tumour | |
|----------------------------------|--|
| TX | Primary tumour cannot be assessed |
| T0 | No evidence of primary tumour |
| Urethra (male and female) | |
| Ta | Non-invasive papillary, polypoid, or verrucous carcinoma |
| Tis | Carcinoma <i>in situ</i> |
| T1 | Tumour invades subepithelial connective tissue |
| T2 | Tumour invades any of the following: corpus spongiosum, prostate, periurethral muscle |
| T3 | Tumour invades any of the following: corpus cavernosum, beyond prostatic capsule, anterior vagina, bladder neck (extraprostatic extension) |
| T4 | Tumour invades other adjacent organs (invasion of the bladder) |

| Urothelial (transitional cell) carcinoma of the prostate | |
|---|---|
| Tis pu | Carcinoma <i>in situ</i> , involvement of prostatic urethra |
| Tis pd | Carcinoma <i>in situ</i> , involvement of prostatic ducts |
| T1 | Tumour invades subepithelial connective tissue (for tumours involving prostatic urethra only) |
| T2 | Tumour invades any of the following: prostatic stroma, corpus spongiosum, periurethral muscle |
| T3 | Tumour invades any of the following: corpus cavernosum, beyond prostatic capsule, bladder neck (extraprostatic extension) |
| T4 | Tumour invades other adjacent organs (invasion of the bladder or rectum) |
| N - Regional Lymph Nodes | |
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Metastasis in a single lymph node |
| N2 | Metastasis in multiple lymph node |
| M - Distant Metastasis | |
| M0 | No distant metastasis |
| M1 | Distant metastasis |

4.2 Tumour grade

The former World Health Organization (WHO) grading system of 1973, which differentiated urothelial carcinomas into three different grades (G1-G3), has been replaced by the grading system of 2004 that differentiates urothelial UC into papillary urothelial neoplasm of low malignant potential (PUNLMP), low grade and high grade. Non-urothelial UC is graded by a trinomial system that differentiates between well-differentiated (G1), moderately-differentiated (G2), and poorly-differentiated tumours (G3). Table 4.2 lists the different grading systems according to the WHO 1973 and 2004 systems [29]. The 2004 classification corresponds to the new 2016 WHO classification [30].

Table 4.2: Histopathological grading of urothelial and non-urothelial primary urethral carcinoma [29]

| Urothelial urethral carcinoma | |
|--|--|
| PUNLMP | Papillary urothelial neoplasm of low malignant potential |
| Low grade | Well differentiated |
| High grade | Poorly differentiated |
| Non-urothelial urethral carcinoma | |
| Gx | Tumour grade not assessable |
| G1 | Well differentiated |
| G2 | Moderately differentiated |
| G3 | Poorly differentiated |

4.3 Guideline for staging and classification systems

| Recommendation | LE | Strength rating |
|---|-----------|------------------------|
| Use the 2017 TNM classification and 2004/2016 WHO grading systems for pathological staging and grading of primary urethral carcinoma. | 3 | Strong |

5. DIAGNOSTIC EVALUATION AND STAGING

5.1 History

When becoming clinically apparent, most patients (45-57%) with primary UC present with symptoms associated with locally advanced disease (T3/T4) [28, 29, 31]. At initial presentation visible haematuria or bloody urethral discharge is reported in up to 62% of the cases. Further symptoms of locally advanced disease include; an extraurethral mass (52%), bladder outlet obstruction (48%), pelvic pain (33%), urethrocutaneous fistula (10%), abscess formation (5%) or dyspareunia [31].

5.2 Clinical examination

In men, physical examination should comprise palpation of the external genitalia for suspicious indurations or masses and digital rectal examination [32]. In women, further pelvic examination with careful inspection and palpation of the urethra should be performed, especially in those with primary onset of irritative or obstructive voiding. In addition, bimanual examination, when necessary under general anaesthesia, should be performed for local clinical staging and to exclude the presence of colorectal or gynaecological malignancies. Bilateral inguinal palpation should be conducted to assess the presence of enlarged lymph nodes (LNs), describing location, size and mobility [33].

5.3 Urinary cytology

Cytological assessment of urine specimens in suspect cases of primary UC should be conducted according to the Paris system [34]. The role of urinary cytology in primary UC is limited since its sensitivity ranges between 55% and 59% [35]. Detection rates depend on the underlying histological entity. In male patients, the sensitivity for UC and SCC was reported to be 80% and 50%, respectively, whereas in female patients, sensitivity was found to be 77% for SCC and 50% for UC [34].

5.4 Diagnostic urethrocystoscopy and biopsy

Diagnostic urethrocystoscopy and biopsy enables primary assessment of a urethral tumour in terms of tumour extent, location and underlying histology [32]. To enable accurate pathological assessment of surgical margins, biopsy sites (proximal/distal end) should be marked and sent together with clinical information to the pathologist.

Careful cystoscopic examination is necessary to exclude the presence of concomitant bladder tumours [3, 36]. A cold-cup biopsy enables accurate tissue retrieval for histological analysis and avoids artificial tissue damage. In patients with larger lesions, transurethral resection (optionally in men under penile blood arrest using a tourniquet) can be performed for histological diagnosis. In patients with suspected UC of the prostatic urethra or ducts, resectoscope loop biopsy of the prostatic urethra (between the five and seven o'clock position from the bladder neck and distally around the area of the verumontanum) can contribute to an improved detection rate [37].

5.5 Radiological imaging

Radiological imaging of UC aims to assess local tumour extent and to detect lymphatic and distant metastatic spread. For local staging, there is increasing evidence that magnetic resonance imaging (MRI) is an accurate tool for monitoring tumour response to neoadjuvant chemoradiotherapy and evaluating the extent of local disease prior to exenterative surgery [38]. Imaging for regional LN metastases should concentrate on inguinal and pelvic LNs, using either MRI or computed tomography (CT). Distant staging should concentrate on chest and liver, with CT of the thorax and abdomen in all patients with invasive disease (> cT1N0M0) [38-42]. If imaging of the remainder of the urothelium is required, then CT urography, ideally including a urothelial and excretory phase, should be performed [43].

5.6 Regional lymph nodes

Enlarged LNs in UC often represent metastatic disease [44, 45]. In men, lymphatics from the anterior urethra drain into the superficial- and deep inguinal LNs and, subsequently, to the pelvic (external, obturator and internal iliac) LNs. Conversely, lymphatic vessels of the posterior urethra drain into the pelvic LNs. In women, the lymph of the proximal third drains into the pelvic LN chains, whereas the distal two-thirds initially drain into the superficial- and deep inguinal nodes [46, 47].

Nodal control in UC can be achieved either by regional LN dissection [32], radiotherapy [48] or chemotherapy [44]. Currently, there is still no clear evidence supporting prophylactic bilateral inguinal and/or pelvic lymphadenectomy in all patients with UC. However, in patients with clinically enlarged inguinal/pelvic LNs or invasive tumours, regional lymphadenectomy should be considered as initial treatment since cure might still be achievable with limited disease [32].

5.7 Summary of evidence and guidelines for diagnostic evaluation and staging

| Summary of evidence | LE |
|--|----|
| Patients with clinically enlarged inguinal or pelvic lymph nodes often exhibit pathological lymph node metastasis. | 3 |

| Recommendations | LE | Strength rating |
|---|----|-----------------|
| Use urethroscopy with biopsy and urinary cytology to diagnose urethral carcinoma. | 3 | Strong |
| Assess the presence of distant metastases by computed tomography of the thorax and abdomen. | 3 | Strong |
| Use pelvic magnetic resonance imaging to assess the local extent of urethral tumour (mapping tumour extension). | 3 | Strong |

6. PROGNOSIS

6.1 Long-term survival after primary urethral carcinoma

According to the RARECARE project, the mean one- and five-year overall survival (OS) in patients with UC in Europe is 71% and 54%, respectively [9]. With longer follow-up, a SEER analysis of 1,615 cases reported median five- and ten-year OS rates of 46% and 29%, respectively. Cancer-specific survival (CSS) at five and ten years was 68% and 60%, respectively [10].

6.2 Predictors of survival in primary urethral carcinoma

In Europe, mean five-year OS does not substantially differ between the sexes [9, 49]. Predictors of decreased survival in patients with primary UC are:

- advanced age (> 65 years) and black race [9, 49, 50];
- stage, grade, nodal involvement [45] and metastasis [26];
- tumour size and proximal tumour location [26];
- extent of surgical treatment and treatment modality [26, 50];
- underlying histology [9, 27, 50];
- presence of concomitant bladder cancer [36];
- location of recurrence (urethral vs. non-urethral) [51].

Some limitations have to be taken into account in the interpretation of these results. In the Dutch study, the numbers were low (n = 91) [28]. In the large SEER database (n = 2,046), therapy is not well specified in relation to survival [27]. Finally, in contrast to the RARECARE project [9], the opposite findings were reported in the SEER database in relation to the role of histology on survival in male patients [50].

6.3 Summary of evidence for prognosis

| Summary of evidence | LE |
|--|----|
| Risk factors for survival in primary urethral carcinoma are: age, race, tumour stage and grade, nodal stage, presence of distant metastasis, histological type, tumour size, tumour location, concomitant bladder cancer and type and modality of treatment. | 3 |

7. DISEASE MANAGEMENT

7.1 Treatment of localised primary urethral carcinoma in males

Previously, treatment of male anterior UC has followed the procedure for penile cancer, with aggressive surgical excision of the primary lesion with a wide safety margin [32]. Distal urethral tumours exhibit significantly improved survival rates compared with proximal tumours [52]. Therefore, optimising treatment of distal UC has become the focus of clinicians to improve functional outcome and quality of life, while preserving oncological safety. A retrospective series found no evidence of local recurrence, even with < 5 mm resection margins (median follow-up: 17-37 months), in men with pT1-3N0-2 anterior UC treated with well-defined penis preserving surgery and additional iliac/inguinal lymphadenectomy for clinically suspected LN disease [53]. This suggests that prognosis is mainly determined by nodal stage. Similar results for the feasibility of penile-preserving surgery have also been reported in recent series [54, 55]. However, a recent series on patients treated with penis-preserving surgery for distal urethral cancer reported a higher risk of progression in patients with positive proximal margins, which was also more frequently present in cases of lymphovascular and perineural invasion of the primary tumour [56].

7.1.1 Summary of evidence and guidelines for the treatment of primary urethral carcinoma in males

| Summary of evidence | LE |
|---|----|
| In distal urethral tumours performing a partial urethrectomy with a minimal safety margin does not increase the risk of local recurrence. | 3 |

| Recommendations | LE | Strength rating |
|--|----|-----------------|
| Offer distal urethrectomy as an alternative to penile amputation in localised anterior urethral tumours, if surgical margins are negative. | 3 | Weak |
| Ensure complete circumferential assessment of the proximal urethral margin if penis-preserving surgery is intended. | 3 | Strong |

7.2 Treatment of localised urethral carcinoma in females

7.2.1 Urethrectomy and urethra-sparing surgery

In women with localised UC, to provide the highest chance of local cure, primary radical urethrectomy should remove all the periurethral tissue from the bulbocavernosus muscle bilaterally and distally, with a cylinder of all adjacent soft tissue up to the pubic symphysis and bladder neck. Bladder neck closure and appendicovesicostomy for primary anterior urethral lesions has been shown to provide satisfactory functional results in women [32].

Recent series have reported outcomes in women with mainly anterior UC undergoing primary treatment with urethra-sparing surgery or radiotherapy, compared to primary urethrectomy, with the aim of maintaining integrity and function of the lower urinary tract [57-59]. In long-term series with a median follow-up of 153-175 months, local recurrence rates in women undergoing partial urethrectomy with intra-operative frozen section analysis were 22-60%, and distal sleeve resection of > 2 cm resulted in secondary urinary incontinence in 42% of patients who required additional reconstructive surgery [58].

Ablative surgical techniques, i.e., transurethral resection (TUR) or laser, used for small distal UC, have also resulted in considerable local failure rates of 16%, with a CSS rate of 50%. This emphasises the critical role of local tumour control in women with distal UC to prevent local and systemic progression [57].

7.2.2 Radiotherapy

In women, radiotherapy was investigated in several older long-term series with a medium follow up of 91-105 months [48, 53]. With a median cumulative dose of 65 Gy (range: 40-106 Gy), the five year local control rate was 64% and seven-year CSS was 49% [48]. Most local failures (95%) occurred within the first two years after primary treatment [48]. The extent of urethral tumour involvement was found to be the only parameter independently associated with local tumour control but the type of radiotherapy (EBRT vs. interstitial brachytherapy) was not [48]. In one study, the addition of brachytherapy to EBRT reduced the risk of local recurrence by a factor of 4.2 [60]. Of note, pelvic toxicity in those achieving local control was considerable (49%), including urethral stenosis, fistula, necrosis, and cystitis and/or haemorrhage, with 30% of the reported complications graded as severe [48].

7.2.3 Summary of evidence and guidelines for the treatment of localised urethral carcinoma in females

| Summary of evidence | LE |
|--|----|
| In anterior tumours, urethra-sparing surgery and local radiotherapy represent alternatives to primary urethrectomy but are associated with increased risk of tumour recurrence and local toxicity. | 3 |

| Recommendations | LE | Strength rating |
|--|----|-----------------|
| Offer urethra-sparing surgery as an alternative to primary urethrectomy to women with anterior urethral tumours, if negative surgical margins can be achieved intra-operatively. | 3 | Weak |
| Offer local radiotherapy as an alternative to urethral surgery to women with localised urethral tumours, but discuss local toxicity. | 3 | Weak |

7.3 Multimodal treatment in advanced urethral carcinoma in both genders

7.3.1 Introduction

Multimodal therapy in primary UC consists of definitive surgery plus chemotherapy with the option of additional radiotherapy. Multimodal therapy is often underutilised (16%) in locally advanced disease. It confers an OS benefit in primary UC of urothelial origin [61, 62].

7.3.2 Preoperative platinum-based chemotherapy

Recent retrospective studies have reported that modern platinum-based polychemotherapeutic regimens are effective in advanced primary UC, providing prolonged survival even in LN-positive disease. Moreover, they have emphasised the critical role of surgery after chemotherapy to achieve long-term survival in patients with locally advanced UC.

In a series of 39 patients treated with perioperative platinum-based chemotherapy for advanced primary UC within a multicentre study of 124 patients, preoperative chemotherapy was found to be associated with improved progression-free and OS compared to surgery followed by adjuvant chemotherapy [63]. Another series reported outcomes in 44 patients with advanced primary UC treated with specific cisplatin-based polychemotherapeutic regimens according to the underlying histology. The overall response rate for the various regimens was 72% and the median OS 32 months. Patients who underwent surgery after chemotherapy had a significantly improved OS compared with those who were managed with chemotherapy alone [44].

7.3.3 Preoperative chemoradiotherapy in locally advanced squamous cell carcinoma of the urethra

The clinical feasibility of preoperative local radiotherapy with concurrent radiosensitising chemotherapy as an alternative to surgery in locally advanced SCC has been reported in several recent series. This approach offers a potential for genital preservation [63–68]. The largest, and recently updated, series reported outcomes in 25 patients with primary locally advanced SCC of the urethra treated with two cycles of 5-fluorouracil and mitomycin C with concurrent EBRT. A complete response to primary chemoradiotherapy was observed in ~80%. The five-year OS and DSS survival was 52% and 68%, respectively. In this updated series, salvage surgery initiated only in non-responders or in case of local failure, was not reported to be associated with improved survival [64].

7.3.4 Salvage treatment in recurrent primary urethral carcinoma after surgery for primary treatment

A recent multicentre study reported that patients who were treated with surgery for primary therapy, and underwent surgery or radiotherapy-based salvage treatment for recurrent solitary or concomitant urethral disease, demonstrated similar survival rates compared to patients who never developed recurrence after primary treatment [69].

7.3.5 Summary of evidence and guidelines for multimodal treatment in advanced urethral carcinoma in both genders

| Summary of evidence | LE |
|---|----|
| In locally advanced urethral carcinoma, cisplatin-based chemotherapy with curative intent prior to surgery improves survival compared to chemotherapy alone, or surgery followed by chemotherapy. | 3 |
| In locally advanced squamous cell carcinoma (SCC) of the urethra, the prognostic role and timing of surgery after completion of chemoradiotherapy is unclear. | 3 |

| Recommendations | LE | Strength rating |
|--|----|-----------------|
| Discuss treatment of patients with locally advanced urethral carcinoma within a multidisciplinary team of urologists, radio-oncologists and oncologists. | 4 | Strong |
| Systemic therapy in advanced disease should be selected based upon the histology of the tumour. | 3 | Strong |
| In locally advanced urethral carcinoma, use cisplatin-based chemotherapeutic regimens with curative intent prior to surgery. | 3 | Strong |
| In locally advanced SCC of the urethra, offer the combination of curative radiotherapy with radiosensitising chemotherapy for genital preservation. | 3 | Strong |
| Offer salvage surgery or radiotherapy to patients with urethral recurrence after primary treatment. | 3 | Weak |

7.4 Treatment of urothelial carcinoma of the prostate

Local conservative treatment with extensive TUR and subsequent Bacillus-Calmette-Guérin (BCG) instillation is effective in patients with Ta or Tis prostatic UC [70, 71]. Likewise, patients undergoing TUR of the prostate prior to BCG experience improved complete response rates compared with those who do not (95% vs. 66%) [72]. Risk of understaging local extension of prostatic urethral cancer at TUR is increased, especially in patients with ductal or stromal involvement [73]. In smaller series, response rates to BCG in patients with prostatic duct involvement have been reported to vary between 57% and 75% [70, 74]. Some earlier series have reported superior oncological results for the initial use of radical cystoprostatectomy as a primary treatment option in patients with ductal involvement [75, 76]. In 24 patients with prostatic stromal invasion treated with radical cystoprostatectomy, a LN mapping study found that twelve patients had positive LNs, with an increased proportion located above the iliac bifurcation [77].

7.4.1 Summary of evidence and guidelines for the treatment of urothelial carcinoma of the prostate

| Summary of evidence | LE |
|---|----|
| Patients undergoing transurethral resection of the prostate for prostatic urothelial carcinoma (UC) prior to bacillus-Calmette-Guérin (BCG) treatment show superior complete response rates compared to those who do not. | 3 |

| Recommendations | LE | Strength rating |
|--|----|-----------------|
| Offer a urethra-sparing approach with transurethral resection (TUR) and BCG to patients with non-invasive urethral carcinoma or carcinoma <i>in situ</i> of the prostatic urethra and prostatic ducts. | 3 | Strong |
| In patients with non-invasive UC or carcinoma <i>in situ</i> , perform a prior TUR of the prostate to improve response to BCG. | 3 | Weak |
| In patients not responding to BCG, or in patients with extensive ductal or stromal involvement, perform a cystoprostatectomy with extended pelvic lymphadenectomy. | 3 | Strong |

8. FOLLOW-UP

Given the low incidence of primary urethral cancer, follow-up has, so far, not been systematically investigated. Therefore, it seems reasonable to tailor surveillance regimens according to patients' individual risk factors (see Chapter 6.2). In patients undergoing urethra-sparing surgery, it seems prudent to advocate a more extensive follow-up with urinary cytology, urethrocystoscopy and cross-sectional imaging despite the lack of specific data.

9. REFERENCES

1. Boorjian, S.A., *et al.* Risk factors and outcomes of urethral recurrence following radical cystectomy. *Eur Urol*, 2011. 60: 1266.
<https://www.ncbi.nlm.nih.gov/pubmed/21871713>
2. Witjes, J.A., *et al.*, EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Edn. presented at the 33rd EAU Annual Congress Copenhagen in EAU Guidelines 2018: Arnhem. The Netherlands.
<https://uroweb.org/guideline/primary-urethral-carcinoma/>
3. Gakis, G., *et al.* EAU guidelines on primary urethral carcinoma. *Eur Urol*, 2013. 64: 823.
<https://www.ncbi.nlm.nih.gov/pubmed/23582479>
4. Guyatt GH, *et al.* What is "quality of evidence" and why is it important to clinicians? *BMJ* 2008. 336: 995.
<https://www.ncbi.nlm.nih.gov/pubmed/18456631>

5. Guyatt GH, *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008. 336:924.
<https://www.ncbi.nlm.nih.gov/pubmed/18436948>
6. Phillips, B., *et al.* Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick, March 2009.
7. Gatta, G., *et al.* Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer*, 2011. 47: 2493.
<https://www.ncbi.nlm.nih.gov/pubmed/22033323>
8. Brierley, J.D., *et al.*, TNM classification of malignant tumors. UICC International Union Against Cancer. 2017, Wiley/Blackwell. p. 208.
<http://www.uicc.org/resources/tnm>.
9. Visser, O., *et al.* Incidence and survival of rare urogenital cancers in Europe. *Eur J Cancer*, 2012. 48: 456.
<https://www.ncbi.nlm.nih.gov/pubmed/22119351>
10. Swartz, M.A., *et al.* Incidence of primary urethral carcinoma in the United States. *Urology*, 2006. 68: 1164.
<https://www.ncbi.nlm.nih.gov/pubmed/17141838>
11. Medina Perez, M., *et al.* [Squamous carcinoma of the male urethra, its presentation as a scrotal abscess]. *Arch Esp Urol*, 1999. 52: 792.
<https://www.ncbi.nlm.nih.gov/pubmed/10540772>
12. Van de Voorde, W., *et al.* Urethral squamous cell carcinoma associated with urethral stricture and urethroplasty. *Eur J Surg Oncol*, 1994. 20: 478.
<https://www.ncbi.nlm.nih.gov/pubmed/8076714>
13. Colapinto, V., *et al.* Primary carcinoma of the male urethra developing after urethroplasty for stricture. *J Urol*, 1977. 118: 581.
<https://www.ncbi.nlm.nih.gov/pubmed/916053>
14. Mohanty, N.K., *et al.* Squamous cell carcinoma of perineal urethrostomy. *Urol Int*, 1995. 55: 118.
<https://www.ncbi.nlm.nih.gov/pubmed/8533195>
15. Sawczuk, I., *et al.* Post urethroplasty squamous cell carcinoma. *NY State J Med*, 1986. 86: 261.
<https://www.ncbi.nlm.nih.gov/pubmed/3459083>
16. Mohan, H., *et al.* Squamous cell carcinoma of the prostate. *Int J Urol*, 2003. 10: 114.
<https://www.ncbi.nlm.nih.gov/pubmed/12588611>
17. Arva, N.C., *et al.* Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature. *Diagn Pathol*, 2011. 6: 46.
<https://www.ncbi.nlm.nih.gov/pubmed/21627811>
18. Cupp, M.R., *et al.* Detection of human papillomavirus DNA in primary squamous cell carcinoma of the male urethra. *Urology*, 1996. 48: 551.
<https://www.ncbi.nlm.nih.gov/pubmed/8886059>
19. Wiener, J.S., *et al.* Oncogenic human papillomavirus type 16 is associated with squamous cell cancer of the male urethra. *Cancer Res*, 1992. 52: 5018.
<https://www.ncbi.nlm.nih.gov/pubmed/1325290>
20. Ahmed, K., *et al.* Urethral diverticular carcinoma: an overview of current trends in diagnosis and management. *Int Urol Nephrol*, 2010. 42: 331.
<https://www.ncbi.nlm.nih.gov/pubmed/19649767>
21. Chung, D.E., *et al.* Urethral diverticula in women: discrepancies between magnetic resonance imaging and surgical findings. *J Urol*, 2010. 183: 2265.
<https://www.ncbi.nlm.nih.gov/pubmed/20400161>
22. Thomas, A.A., *et al.* Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations. *J Urol*, 2008. 180: 2463.
<https://www.ncbi.nlm.nih.gov/pubmed/18930487>
23. Libby, B., *et al.* Non-surgical treatment of primary female urethral cancer. *Rare Tumors*, 2010. 2: e55.
<https://www.ncbi.nlm.nih.gov/pubmed/21139970>
24. Gandhi, J.S., *et al.* Clear cell adenocarcinoma of the male urethral tract. *Indian J Pathol Microbiol*, 2012. 55: 245.
<https://www.ncbi.nlm.nih.gov/pubmed/22771656>
25. Mehra, R., *et al.* Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. *Am J Pathol*, 2014. 184: 584.
<https://www.ncbi.nlm.nih.gov/pubmed/24389164>
26. Rabbani, F. Prognostic factors in male urethral cancer. *Cancer*, 2011. 117: 2426.
<https://www.ncbi.nlm.nih.gov/pubmed/24048790>

27. Derksen, J.W., *et al.* Primary urethral carcinoma in females: an epidemiologic study on demographical factors, histological types, tumour stage and survival. *World J Urol*, 2013. 31: 147.
<https://www.ncbi.nlm.nih.gov/pubmed/22614443>
28. Golijanin, D., *et al.* Carcinoma in a bladder diverticulum: presentation and treatment outcome. *J Urol*, 2003. 170: 1761.
<https://www.ncbi.nlm.nih.gov/pubmed/14532771>
29. Eble JN, *et al.* WHO Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (IARC WHO Classification of Tumours). 2004, Lyon.
<http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb7/BB7.pdf>
30. Compérat, E., *et al.* Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification. *Histopathology*, 2016. 69: 717.
<https://www.ncbi.nlm.nih.gov/pubmed/27353436>
31. Gheiler, E.L., *et al.* Management of primary urethral cancer. *Urology*, 1998. 52: 487.
<https://www.ncbi.nlm.nih.gov/pubmed/9730466>
32. Karnes, R.J., *et al.* Surgery for urethral cancer. *Urol Clin North Am*, 2010. 37: 445.
<https://www.ncbi.nlm.nih.gov/pubmed/20674699>
33. Blaivas, J.G., *et al.* Periurethral masses: etiology and diagnosis in a large series of women. *Obstet Gynecol*, 2004. 103: 842.
<https://www.ncbi.nlm.nih.gov/pubmed/15121554>
34. Barkan, G.A., *et al.* The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology. *Acta Cytol*, 2016. 60: 185.
<https://www.ncbi.nlm.nih.gov/pubmed/27318895>
35. Touijer, A.K., *et al.* Role of voided urine cytology in diagnosing primary urethral carcinoma. *Urology*, 2004. 63: 33.
<https://www.ncbi.nlm.nih.gov/pubmed/14751342>
36. Gakis, G., *et al.* Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma. *Urol Int*, 2016. 97: 134.
<https://www.ncbi.nlm.nih.gov/pubmed/27462702>
37. Donat, S.M., *et al.* The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. *J Urol*, 2001. 165: 1580.
<https://www.ncbi.nlm.nih.gov/pubmed/11342921>
38. Gourtsoyianni, S., *et al.* MRI at the completion of chemoradiotherapy can accurately evaluate the extent of disease in women with advanced urethral carcinoma undergoing anterior pelvic exenteration. *Clin Radiol*, 2011. 66: 1072.
<https://www.ncbi.nlm.nih.gov/pubmed/21839430>
39. Kim, B., *et al.* Imaging of the male urethra. *Semin Ultrasound CT MR*, 2007. 28: 258.
<https://www.ncbi.nlm.nih.gov/pubmed/17874650>
40. Neitlich, J.D., *et al.* Detection of urethral diverticula in women: comparison of a high resolution fast spin echo technique with double balloon urethrography. *J Urol*, 1998. 159: 408.
<https://www.ncbi.nlm.nih.gov/pubmed/9649250>
41. Ryu, J., *et al.* MR imaging of the male and female urethra. *Radiographics*, 2001. 21: 1169.
<https://www.ncbi.nlm.nih.gov/pubmed/11553824>
42. Stewart, S.B., *et al.* Imaging tumors of the penis and urethra. *Urol Clin North Am*, 2010. 37: 353.
<https://www.ncbi.nlm.nih.gov/pubmed/20674692>
43. Raman, S.P., *et al.* Upper and Lower Tract Urothelial Imaging Using Computed Tomography Urography. *Radiol Clin North Am*, 2017. 55: 225.
<https://www.ncbi.nlm.nih.gov/pubmed/28126213>
44. Dayyani, F., *et al.* Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. *Urol Oncol*, 2013. 31: 1171.
<https://www.ncbi.nlm.nih.gov/pubmed/22534087>
45. Gakis, G., *et al.* Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. *World J Urol*, 2016. 34: 97.
<https://www.ncbi.nlm.nih.gov/pubmed/25981402>
46. Carroll, P.R., *et al.* Surgical anatomy of the male and female urethra. *Urol Clin North Am*, 1992. 19: 339.
<https://www.ncbi.nlm.nih.gov/pubmed/1574824>
47. Sharp, D., *et al.*, Surgery of penile and urethral carcinoma, in *Campbell's Urology*, D. McDougal, A. Wein, L. Kavoussi, A. Novick, A. Partin, C. Peters & P. Ramchandani, Editors. 2012, Saunders Elsevier: Philadelphia, PA, USA.

48. Garden, A.S., *et al.* Primary carcinoma of the female urethra. Results of radiation therapy. *Cancer*, 1993. 71: 3102.
<https://www.ncbi.nlm.nih.gov/pubmed/8490839>
49. Sui, W., *et al.* Outcomes and Prognostic Factors of Primary Urethral Cancer. *Urology*, 2017. 100: 180.
<https://www.ncbi.nlm.nih.gov/pubmed/>
50. Champ, C.E., *et al.* Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. *Urology*, 2012. 80: 374.
<https://www.ncbi.nlm.nih.gov/pubmed/22857759>
51. Gakis, G., *et al.* Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer. *J Clin Oncol (Meeting Abstracts)*, 2015. 33: 4568.
http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.4568
52. Dalbagni, G., *et al.* Male urethral carcinoma: analysis of treatment outcome. *Urology*, 1999. 53: 1126.
<https://www.ncbi.nlm.nih.gov/pubmed/10367840>
53. Smith, Y., *et al.* Penile-preserving surgery for male distal urethral carcinoma. *BJU Int*, 2007. 100: 82.
<https://www.ncbi.nlm.nih.gov/pubmed/17488307>
54. Pedrosa, J.A., *et al.* Distal urethrectomy for localized penile squamous carcinoma in situ extending into the urethra: an updated series. *Int Urol Nephrol*, 2014. 46: 1551.
<https://www.ncbi.nlm.nih.gov/pubmed/24633698>
55. Kulkarni, M., *et al.* MP10-16 Substitution urethroplasty for treatment of distal urethral carcinoma and carcinoma in situ. *J. Urol* 193: e117.
[http://www.jurology.com/article/S0022-5347\(15\)00728-4/abstract](http://www.jurology.com/article/S0022-5347(15)00728-4/abstract)
56. Torbrand, C., *et al.* Diagnosing Distal Urethral Carcinomas in Men Might Be Only the Tip of the Iceberg. *Clin Genitourin Cancer*, 2017. 15: e1131.
<https://www.ncbi.nlm.nih.gov/pubmed/28784424>
57. Dimarco, D.S., *et al.* Surgical treatment for local control of female urethral carcinoma. *Urol Oncol*, 2004. 22: 404.
<https://www.ncbi.nlm.nih.gov/pubmed/15464921>
58. DiMarco, D.S., *et al.* Outcome of surgical treatment for primary malignant melanoma of the female urethra. *J Urol*, 2004. 171: 765.
<https://www.ncbi.nlm.nih.gov/pubmed/14713806>
59. Shim, J.S., *et al.* Anterior urethrectomy for primary carcinoma of the female urethra mimicking a urethral caruncle. *Int Neurourol J*, 2013. 17: 197.
<https://www.ncbi.nlm.nih.gov/pubmed/24466468>
60. Milosevic, M.F., *et al.* Urethral carcinoma in women: results of treatment with primary radiotherapy. *Radiother Oncol*, 2000. 56: 29.
<https://www.ncbi.nlm.nih.gov/pubmed/10869752>
61. Cahn, D.B., *et al.* Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. *Urol Oncol*, 2017. 35: 670 e15.
<https://www.ncbi.nlm.nih.gov/pubmed/>
62. Dayyani, F., *et al.* Management of advanced primary urethral carcinomas. *BJU Int*, 2014. 114: 25.
<https://www.ncbi.nlm.nih.gov/pubmed/24447439>
63. Gakis, G., *et al.* Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. *Ann Oncol*, 2015. 26: 1754.
<https://www.ncbi.nlm.nih.gov/pubmed/25969370>
64. Kent, M., *et al.* Combined chemoradiation as primary treatment for invasive male urethral cancer. *J Urol*, 2015. 193: 532.
<https://www.ncbi.nlm.nih.gov/pubmed/25088950>
65. Gakis, G. Editorial Comment to Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. *Int J Urol*, 2014. 21: 424.
<https://www.ncbi.nlm.nih.gov/pubmed/24251884>
66. Itoh, J., *et al.* Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. *Int J Urol*, 2014. 21: 422.
<https://www.ncbi.nlm.nih.gov/pubmed/24251859>
67. Hara, I., *et al.* Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy. *Int J Urol*, 2004. 11: 678.
<https://www.ncbi.nlm.nih.gov/pubmed/15285764>
68. Cohen, M.S., *et al.* Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. *J Urol*, 2008. 179: 536.
<https://www.ncbi.nlm.nih.gov/pubmed/18076921>

69. Gakis, G., *et al.* The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. *Urol Oncol*, 2018. 36: 10 e7.
<https://www.ncbi.nlm.nih.gov/pubmed/29055518>
70. Palou Redorta, J., *et al.* Intravesical instillations with bacillus calmette-guerin for the treatment of carcinoma in situ involving prostatic ducts. *Eur Urol*, 2006. 49: 834.
<https://www.ncbi.nlm.nih.gov/pubmed/16426729>
71. Picozzi, S., *et al.* Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. *J Urol*, 2012. 188: 2046.
<https://www.ncbi.nlm.nih.gov/pubmed/23083867>
72. Gofrit, O.N., *et al.* Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guerin immunotherapy? *BJU Int*, 2009. 103: 905.
<https://www.ncbi.nlm.nih.gov/pubmed/19021623>
73. Njinou Ngninkeu, B., *et al.* Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. *J Urol*, 2003. 169: 149.
<https://www.ncbi.nlm.nih.gov/pubmed/12478124>
74. Palou, J., *et al.* Urothelial carcinoma of the prostate. *Urology*, 2007. 69: 50.
<https://www.ncbi.nlm.nih.gov/pubmed/17280908>
75. Hillyard, R.W., Jr., *et al.* Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin. *J Urol*, 1988. 139: 290.
<https://www.ncbi.nlm.nih.gov/pubmed/3339727>
76. Solsona, E., *et al.* The prostate involvement as prognostic factor in patients with superficial bladder tumors. *J Urol*, 1995. 154: 1710.
<https://www.ncbi.nlm.nih.gov/pubmed/7563328>
77. Vazina, A., *et al.* Stage specific lymph node metastasis mapping in radical cystectomy specimens. *J Urol*, 2004. 171: 1830.
<https://www.ncbi.nlm.nih.gov/pubmed/15076287>

10. CONFLICT OF INTEREST

All members of the Muscle-invasive and Metastatic Bladder Cancer Guidelines Panel have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website: <http://www.uroweb.org/guidelines/primary-urethral-carcinoma/>.

This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

11. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.

If a publisher and/or location is required, include:

EAU Guidelines Office, Arnhem, The Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>

References to individual guidelines should be structured in the following way:

Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.